Pharmaceutical

Emergent scores US medical countermeasure contracts worth over $250m

Emergent will supply vaccines for anthrax and smallpox, VIV for treating smallpox vaccine complications, and a botulism antitoxin.

Jul 4, 2024 - 04:00
Emergent scores US medical countermeasure contracts worth over $250m
Emergent will supply vaccines for anthrax and smallpox, VIV for treating smallpox vaccine complications, and a botulism antitoxin.
Read the original article

Tags:

Previous Article

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

Next Article

EMA approves Sanofi’s Dupixent for COPD treatment in adults

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA approves Analog and Dipharma’s ANDA for nitisinone capsules

FDA approves Analog and Dipharma’s ANDA for nitisinone ...

Jun 1, 2023

STAT+: Lawmakers circle parents’ rights in gender-affirming care hearing

STAT+: Lawmakers circle parents’ rights in gender-affir...

Jul 30, 2023

HHS fills key vaccine advisory panel slots

HHS fills key vaccine advisory panel slots

Feb 15, 2024